Enanta Pharmaceuticals (ENTA) EBIT Margin (2012 - 2026)
Enanta Pharmaceuticals posted quarterly EBIT Margin of 69.07% for Q1 2026, up 9525.0% year-on-year from 0.72% in Q1 2025, and down 14.26% on a QoQ basis from 60.45% in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of EBIT Margin data on file, last reported at 69.07% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 9525.0% year-over-year to 69.07%; the trailing twelve-month figure through Mar 2026 stood at 87.24% (up 7116.0% YoY), and the FY2025 full-year result was 130.65%, up 4927.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 69.07%, down from 60.45% in the prior quarter.
- Across five years, EBIT Margin topped out at 60.45% in Q4 2025 and bottomed at 221.7% in Q1 2023.
- The 5-year median for EBIT Margin is 163.9% (2023), against an average of 151.2%.
- The widest annual swing landed in 2023, when EBIT Margin sank 6652 bps; it then surged 9525 bps in 2026.
- A 5-year view of EBIT Margin shows it stood at 127.25% in 2022, then sank by 52 bps to 193.78% in 2023, then gained by 28 bps to 138.82% in 2024, then surged by 56 bps to 60.45% in 2025, then dropped by 14 bps to 69.07% in 2026.
- The last three EBIT Margin figures came in at 69.07% (Q1 2026), 60.45% (Q4 2025), and 121.56% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -69.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.07% |
| Dec 31, 2025 | -60.45% |
| Sep 30, 2025 | -121.56% |
| Jun 30, 2025 | -103.16% |
| Mar 31, 2025 | -164.32% |
| Dec 31, 2024 | -138.82% |
| Sep 30, 2024 | -204.38% |
| Jun 30, 2024 | -134.58% |
| Mar 31, 2024 | -192.13% |
| Dec 31, 2023 | -193.78% |
| Sep 30, 2023 | -163.90% |
| Jun 30, 2023 | -194.33% |
| Mar 31, 2023 | -221.70% |
| Dec 31, 2022 | -127.25% |
| Sep 30, 2022 | -133.13% |
| Jun 30, 2022 | -167.05% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -109.99% |
| Sep 30, 2021 | -143.06% |
| Jun 30, 2021 | -156.53% |
| Mar 31, 2021 | -147.53% |
| Dec 31, 2020 | -38.75% |
| Sep 30, 2020 | -83.72% |
| Jun 30, 2020 | -122.51% |
| Mar 31, 2020 | -43.00% |
| Dec 31, 2019 | 24.48% |
| Sep 30, 2019 | 12.53% |
| Jun 30, 2019 | 8.46% |
| Mar 31, 2019 | -3.29% |
| Dec 31, 2018 | 39.86% |
| Sep 30, 2018 | 51.26% |
| Jun 30, 2018 | 39.54% |
| Mar 31, 2018 | 38.27% |
| Dec 31, 2017 | 37.73% |
| Sep 30, 2017 | 71.51% |
| Jun 30, 2017 | -174.80% |
| Mar 31, 2017 | -106.11% |
| Dec 31, 2016 | -67.64% |
| Sep 30, 2016 | -24.13% |
| Jun 30, 2016 | -7.79% |
| Mar 31, 2016 | -4.34% |
| Dec 31, 2015 | 73.47% |
| Sep 30, 2015 | 25.49% |
| Jun 30, 2015 | 14.68% |
| Mar 31, 2015 | 84.65% |
| Dec 31, 2014 | 90.60% |
| Sep 30, 2014 | -201.97% |
| Jun 30, 2014 | 82.98% |
| Mar 31, 2014 | -237.36% |
| Dec 31, 2013 | -611.09% |
| Sep 30, 2013 | -348.48% |
| Jun 30, 2013 | -253.37% |
| Mar 31, 2013 | -334.53% |
| Dec 31, 2012 | 78.64% |
| Sep 30, 2012 | -220.45% |
| Jun 30, 2012 | -138.79% |
| Mar 31, 2012 | 87.78% |